Try our Advanced Search for more refined results
IN RE: ABILIFY (ARIPIPRAZOLE) PRODUCTS LIABILITY LITIGATION
Case Number:
3:16-md-02734
Court:
Nature of Suit:
Multi Party Litigation:
Multi-district Litigation
Judge:
Firms
- Arnold & Porter
- Aylstock Witkin
- Baker Donelson
- Baker McKenzie
- Carlton Fields
- Cory Watson Attorneys
- Hogan Lovells
- Joseph Cohen & Del Vecchio
- Kirkland & Ellis
- Kobre & Kim
- Lieff Cabraser
- Moore Hill & Westmoreland
- Robins Kaplan
- Winston & Strawn
Companies
Sectors & Industries:
-
October 10, 2019
19 Abilify Claims Tossed As Lacking Proof In MDL Settlement
A Florida federal judge overseeing multidistrict litigation over side effects of the antipsychotic drug Abilify dismissed another 19 individual cases Thursday as a sanction for those consumers' failures to comply with court orders following the announcement of a global settlement in February.
-
September 24, 2019
Abilify MDL Judge Boots 149 Claimants From Settlement
A Florida federal judge dismissed 149 cases Tuesday from multidistrict litigation over side effects of the antipsychotic drug Abilify as a sanction for those consumers' failures to comply with court orders following the announcement of a global settlement in February.
-
February 26, 2019
Bristol-Myers Ends Abilify MDL With Confidential Settlement
Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. have reached a confidential global settlement with plaintiffs in multidistrict litigation over side effects of their antipsychotic drug Abilify, according to a case management order entered Tuesday in the Northern District of Florida.
-
January 31, 2019
Abilify MDL Plaintiffs Ordered To Defend Their Cases
A Florida federal judge on Thursday ordered more than 400 plaintiffs in multidistrict litigation against Bristol-Myers Squibb and Otsuka Pharmaceuticals over antipsychotic drug Abilify's side effects to show why their claims should not be outright dismissed after they failed to submit court-ordered information.
-
January 16, 2019
Drugmakers Aim To Bump Delinquent Plaintiffs In Abilify MDL
Bristol-Myers Squibb and Otsuka Pharmaceuticals asked a Florida federal judge Wednesday to require more than 550 plaintiffs to show why their claims should not be dismissed in the multidistrict legislation over the antipsychotic drug Abilify's side effects after they failed to submit plaintiff profile forms.
-
April 30, 2018
3 Fla. Bellwether Cases Settled In Abilify MDL
Bristol-Myers Squibb and Otsuka Pharmaceuticals have reached settlement agreements with consumers in three cases scheduled for bellwether trials in Florida this summer in multidistrict litigation over side effects of the antipsychotic drug Abilify, according to a Saturday order.
-
April 05, 2018
Otsuka, Bristol Seek Quick Win On Abilify Fail-To-Warn Claims
Otsuka Pharmaceutical Co. Ltd. and Bristol-Myers Squibb Co. are looking to narrow one of three cases set for trial in multidistrict litigation over side effects of the antipsychotic drug Abilify, arguing the consumers' failure-to-warn claims are unsupported.
-
March 16, 2018
Summary Judgment Denial Clears Path For Abilify Trials
A Florida federal judge late Thursday released a redacted version of an order denying a bid for summary judgment from Otsuka Pharmaceutical and Bristol-Meyers Squibb in multidistrict litigation over alleged side effects of the anti-psychotic drug Abilify, paving the way for trials in consumers' cases this summer.
-
March 13, 2018
Judge Schedules First 3 Trials In Abilify MDL
A Florida federal court settled upon a random order for the first three cases that will be tried in multidistrict litigation over side effects of the antipsychotic drug Abilify after consumers who brought the suits were unable to reach an agreement with the drugmakers Bristol-Meyers Squibb and Otsuka Pharmaceutical.
-
February 13, 2018
Bristol-Myers Hit With Sanctions Bid Over Abilify Notebooks
A class of consumers suing drugmakers over side effects of the antipsychotic drug Abilify asked a Florida federal judge Monday to sanction defendant Bristol-Myers Squibb, alleging a pattern of obstructing discovery in the case and accusing the company's counsel of making false statements to the court.